Pair page
Eloralintide with Retatrutide
Mechanism-tag overlap and published literature for Eloralintide and Retatrutide, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
selective-amylin-receptor-agonist
incretin-peptidetriple-receptor-agonist
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Eloralintide and Retatrutide have published these mechanism-level observations. Not a co-administration recommendation.
GLP-1 / GIP / glucagon tri-agonist in Phase 3. The other next-generation Lilly obesity asset. Retatrutide and eloralintide may become complementary Lilly products addressing different patient segments and combination possibilities.
Quick facts
Eloralintide
Retatrutide
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | Eloralintide | Eli Lilly and Company. Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight. Press release, November 6, 2025. (Phase 2 topline announcement; Phase 3 enrollment initi… | human trial, Phase 3 |
| 2025 | Eloralintide | Billings LK, Hansen HH, Dam-Larsen S, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025. PMID: 41207310. (NCT06230523 — pivotal Phase 2; up to 20… PMID 41207310 | human trial, Phase 2 |
| 2023 | Eloralintide | Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-730.… PMID 37515693 | human trial, Phase 2 |
| 2021 | Eloralintide | Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. PMID:… PMID 34798049 | human trial, Phase 2 |
| — | Eloralintide | ClinicalTrials.gov NCT06230523 — A Study of LY3841136 in Adult Participants With Obesity or Overweight. (Pivotal Phase 2.) | human trial, Phase 2 |
| — | Eloralintide | ClinicalTrials.gov NCT06603571 — A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes. (Combination Phase 2.) | human trial, Phase 2 |
| — | Eloralintide | ClinicalTrials.gov NCT06297616, NCT06916091 — Additional Phase 2 eloralintide monotherapy programs. | human trial, Phase 2 |
| 2025 | Eloralintide | Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. 2025. PMID: 41559929. (Phase 1 multiple-ascending-dose results; 100 participants, up to ~11% weight loss at 12 weeks.) PMID 41559929 | human trial, Phase 1 |
| — | Eloralintide | ClinicalTrials.gov NCT05295940 — A Study of LY3841136 in Healthy Participants. (Phase 1 SAD/MAD.) | human trial, Phase 1 |
| 2025 | Eloralintide | Briere DA, Bueno AB, Gimeno RE, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025. PMID: 41109426. (Full translational characterization; AMY1R selectivity, preclinical weigh… PMID 41109426 | preclinical, in vivo |
| 2025 | Eloralintide | Briere DA, Long A, Bullock DM, et al. 849-P: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide. Diabetes 2025;74(Suppl 1):849-P. (ADA 2025 scientific sessions prec… | preclinical, in vivo |
| 2025 | Eloralintide | Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus. Nat Rev Endocrinol. 2025;21:482-494. (Modern review of the amylin drug class including eloralintide context.) | review |
| 2025 | Retatrutide | Rosenstock J, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025. PMID: 40609566. PMID 40609566 | human trial, Phase 2 |
| 2024 | Retatrutide | Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PMID: 38858523. PMID 38858523 | human trial, Phase 2 |
| 2023 | Retatrutide | Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315. DOI: 10.1056/NEJMoa2301972. PMID 37366315 | human trial, Phase 2 |
| 2023 | Retatrutide | Rosenstock J, Frías JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544.… PMID 37385280 | human trial, Phase 2 |
| 2025 | Retatrutide | Eli Lilly and Company. Topline TRIUMPH-4 readout — retatrutide in adults with obesity and knee osteoarthritis. Press release, October 2025. | human trial |
| 2023 | Retatrutide | Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131. (Comparator reference.) PMID 37952131 | human trial |
| 2022 | Retatrutide | Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024. (Comparator reference.) PMID 35658024 | human trial |
| 2021 | Retatrutide | Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185. (Comparator reference.) PMID 33567185 | human trial |
| — | Retatrutide | Kjeldsen SAS, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. PMID: 41090431. PMID 41090431 | human trial |
| — | Retatrutide | ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Adult Participants Who Have Obesity or Are Overweight With Weight-Related Medical Problems (TRIUMPH-1). NCT05929066. | human trial |
| — | Retatrutide | ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Adult Participants With Obesity and Type 2 Diabetes (TRIUMPH-2). NCT05929079. | human trial |
| — | Retatrutide | ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight With Osteoarthritis of the Knee (TRIUMPH-4). NCT05931367. | human trial |
Related pair pages
More research context
Frequently asked
Have Eloralintide and Retatrutide been studied together?
Researchers have published mechanistic-level co-administration discussion of Eloralintide and Retatrutide. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Eloralintide and Retatrutide share?
Eloralintide and Retatrutide do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Eloralintide and Retatrutide?
Eloralintide: Investigational — Phase 3 enrollment initiated late 2025. Retatrutide: Investigational (Phase 3). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Eloralintide and Retatrutide?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Eloralintide profile and the Retatrutide profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026